Aicura Medical (Germany)

Aicura Medical is a Berlin, Germany-based company operating in the field of AI-native clinical development. According to its official website, the company positions itself around a single core thesis: that the bottleneck in AI-driven drug development is not the models themselves but the underlying data substrate. Aicura Medical builds technology intended to turn fragmented, multimodal clinical data — spanning imaging, fluid biomarkers, and longitudinal patient trajectories — into one computable, AI-ready substrate so that clinical trials can be designed, enriched, and run with greater precision. The company's platform is organized into three layers. The first is a patient graph, which brings each patient's fragmented history across imaging, biomarkers, and time into a single computable view that models can use. The second is a data layer, described as the environment clinical teams work in directly, allowing them to query, explore, and model against one harmonized substrate without re-engineering data for every analysis, while retaining ownership of both the data and the work built on it. The third is an AI layer, comprising models that turn the substrate into trial enrichment, using state-of-the-art multimodal architectures and extending toward large pre-trained models across complex data modalities. Aicura Medical focuses on neurodegeneration, which it describes as one of the therapeutic areas where patients differ most in how they progress and whether they respond. The company argues that a computable substrate can turn messy trial histories into sharper, smaller, and faster studies. Its stated applications include trial design and simulation — testing eligibility, power, and design choices against real historical data before committing to a protocol — and prognostic and predictive enrichment, selecting the patients a trial needs in order to cut sample size and screen-failure rates. The company is headquartered in Berlin, Germany, and is privately held. It operates in the clinical research and drug development technology space, serving the needs of trial sponsors and clinical teams working in complex therapeutic areas. Its official web presence is aicura-medical.com.

Aicura Medical is a Berlin, Germany-based company operating in the field of AI-native clinical development. Public information about the company is limited to its official website and a Wikidata entry identifying it as a company in Berlin, Germany. The company's own materials describe its mission as making the patient computable: turning fragmented, multimodal clinical data into one computable AI-ready substrate so that trials in neurodegeneration are designed, enriched, and run with far greater precision. Aicura Medical frames its work around a diagnosis of the AI-driven drug development landscape. In its account, models are not the bottleneck; the data substrate is. The signal that separates responders from non-responders, and fast progressors from slow, sits across imaging, fluid biomarkers, and longitudinal trajectories that trial systems never bring together. Aicura Medical's stated approach is to make that data computable once, so that every analysis and every model runs on the same integrated view of the patient. The company's platform is presented in three layers. The patient graph brings each patient's fragmented history, across imaging, biomarkers, and time, into a single computable view that models can use. The data layer is the environment clinical teams work in directly; they query, explore, and model against one harmonized substrate without re-engineering the data for every analysis, and they own both the data and the work built on it. The AI layer comprises the models that turn the substrate into trial enrichment, using state-of-the-art multimodal architectures today and extending to large pre-trained models across complex data modalities. Aicura Medical focuses on neurodegeneration, which it characterizes as one of the therapeutic areas where patients differ most in how they progress and whether they respond. The company states that a computable substrate turns messy trial histories into sharper, smaller, faster studies. Its described applications include trial design and simulation — testing eligibility, power, and design choices against real historical data before committing a protocol — and prognostic and predictive enrichment, selecting the patients a trial needs in order to cut sample size and screen-failure rates. The company is headquartered in Berlin, Germany, and is privately held. No founding year, founder, ownership, or funding details are available in the supplied evidence.

AI-native clinical development platform making the patient computable, focused on neurodegeneration trials.

• Patient graph

  Brings each patient's fragmented history, across imaging, biomarkers, and time, into a single computable view that models can actually use.

• Data Layer

  The environment clinical teams work in directly. They query, explore, and model against one harmonized substrate, without re-engineering the data for every analysis, and own both the data and the work built on it.

• AI Layer

  The models that turn the substrate into trial enrichment. State-of-the-art multimodal architectures today, extending to large pre-trained models across complex data modalities.

• Trial design & simulation

  Test eligibility, power, and design choices against real historical data before committing a protocol.

• Prognostic & predictive enrichment

  Select the patients a trial needs, cutting sample size and screen-failure rates.

1. 1AICURA - AI-native clinical developmentaicura-medical.com
2. 2Aicura Medical (Germany) - Wikidatawikidata.org